US Equity
CLLS
— Cellectis SACellectis SA is a clinical-stage biotechnology company that develops gene-edited allogeneic CAR-T cell therapies for the treatment of cancer.
💰 Market cap: $208.35M📍 8, rue de la Croix Jarry, PARIS, ILE-DE-FRANCE, 75013 FR🏷️ Biotechnology & Medical Research💵 Previous close: $2.84🔢 4,694 credits left
Add Column
All
Trend
| Date ▾ | Close ▾ |
|---|---|
| 2026-07-24 | $2.84 |
| 2026-07-23 | $2.77 |
| 2026-07-22 | $2.80 |
| 2026-07-21 | $2.69 |
| 2026-07-20 | $2.60 |
| 2026-07-17 | $2.63 |
| 2026-07-16 | $2.67 |
| 2026-07-15 | $2.81 |
| 2026-07-14 | $2.88 |
| 2026-07-13 | $2.90 |
| 2026-07-10 | $2.99 |
| 2026-07-09 | $3.17 |
| 2026-07-08 | $3.09 |
| 2026-07-07 | $3.22 |
| 2026-07-06 | $3.29 |
| 2026-07-02 | $3.30 |
| 2026-07-01 | $2.94 |
| 2026-06-30 | $3.00 |
| 2026-06-29 | $2.94 |
| 2026-06-26 | $2.83 |
| 2026-06-25 | $2.89 |
| 2026-06-24 | $2.79 |
| 2026-06-23 | $2.90 |
| 2026-06-22 | $2.82 |
| 2026-06-18 | $2.98 |
| 2026-06-17 | $3.08 |
| 2026-06-16 | $3.05 |
| 2026-06-15 | $3.11 |
| 2026-06-12 | $3.09 |
| 2026-06-11 | $3.09 |
| 2026-06-10 | $3.18 |
| 2026-06-09 | $2.99 |
| 2026-06-08 | $2.93 |
| 2026-06-05 | $3.06 |
| 2026-06-04 | $3.15 |
| 2026-06-03 | $3.09 |
| 2026-06-02 | $3.38 |
| 2026-06-01 | $3.48 |
| 2026-05-29 | $3.52 |
| 2026-05-28 | $3.63 |
| 2026-05-27 | $3.63 |
| 2026-05-26 | $3.67 |
| 2026-05-22 | $3.50 |
| 2026-05-21 | $3.52 |
| 2026-05-20 | $3.66 |
| 2026-05-19 | $3.63 |
| 2026-05-18 | $3.85 |
| 2026-05-15 | $3.92 |
| 2026-05-14 | $4.07 |
| 2026-05-13 | $3.98 |
| 2026-05-12 | $3.96 |
| 2026-05-11 | $3.98 |
| 2026-05-08 | $3.85 |
| 2026-05-07 | $3.86 |
| 2026-05-06 | $3.95 |
| 2026-05-05 | $3.76 |
| 2026-05-04 | $3.70 |
| 2026-05-01 | $3.95 |
| 2026-04-30 | $3.90 |
| 2026-04-29 | $3.73 |
| 2026-04-28 | $4.00 |